U.S. markets closed

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.46-0.22 (-2.86%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close7.68
Open7.72
Bid7.35 x 1300
Ask7.47 x 800
Day's Range7.38 - 7.72
52 Week Range7.13 - 11.68
Volume163,824
Avg. Volume251,263
Market Cap323.162M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-0.21
Earnings DateAug 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CytoSorbents to Report Second Quarter 2021 Operating and Financial Results
    PR Newswire

    CytoSorbents to Report Second Quarter 2021 Operating and Financial Results

    CytoSorbents Corporation (NASDAQ: CTSO) a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, will report second quarter 2021 operating and financial results after the market close on August 3, 2021.

  • Here's Why Cytosorbents Is Up 17% Today
    Motley Fool

    Here's Why Cytosorbents Is Up 17% Today

    Shares of Cytosorbents Corporation (NASDAQ: CTSO) jumped 17.3% on Tuesday, spurred higher by news that the Investigational Device Exemption (IDE) request for its DrugSorb-ATR Antithrombotic Removal system has been approved by the U.S. Food and Drug Administration, allowing clinical trials of the device to move forward. Cytosorbents' DrugSorb-ATR Antithrombotic Removal device just cleared another regulatory hurdle. Exempt from certain other steps that some medical devices must go through, the company can now begin testing the device, which allows patients undergoing heart bypass surgeries to curb the amount of blood-thinning drug ticagrelor in the bloodstream during and after the procedure.

  • CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery
    Benzinga

    CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery

    CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb Antithrombotic Removal (ATR) system for intraoperative ticagrelor removal during cardiothoracic surgery. This study is being performed under the previously announced FDA Breakthrough Designation received in April 2020. STAR-T will enroll up to 120 patients, and enrollment is expected to begin soon. The study's primary endpoint will evaluate whethe